Treatment Use Study for Advanced Melanoma.

Pfizer

Status

Conditions: Advanced Unresectable Melanoma

Treatments: Drug: CP-675,206

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT00584493

A3671028

Details and patient eligibility

About

The purpose of this study is to provide access to CP-675,206 for patients with advanced unresectable melanoma and who have the potential to gain benefit from this treatment and who are not eligible for participation in other CP-675,206 studies.

Full description

This is an expanded access trial that canceled prior to enrolling patients.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Advanced melanoma with life expectancy of at least 6 months.
• Melanoma must be considered unresectable.
• Patients with stable, treated brain mets must be stable clinically and radiographically and off steroids for at least one month.

Exclusion criteria

• Patients must not be eligible for participation in any ongoing CP-675,206 clinical studies currently open for enrollment.
• History of chronic inflammatory or autoimmune disease.
• History of inflammatory bowel disease, celiac disease, or other chronic gastrointestinal conditions associated with diarrhea, active colitis, history of diverticulitis.